title: Estrogen-suppressed in vitro maturation: a novel approach to in vitro maturation.
abstract: OBJECTIVE
  To evaluate the laboratory and clinical outcomes of estrogen-suppressed in vitro maturation (ES-IVM), a novel IVM protocol that eliminates the need for FSH stimulation and cycle monitoring.
  
  
  METHODS
  Case series.
  
  
  METHODS
  Academic infertility center.
  
  
  METHODS
  Eighteen infertile couples undergoing ES-IVM (n = 20). Eligible candidates included women ≤38 years old with either polycystic ovarian syndrome, antral follicle count ≥15, and/or history of ovarian hyperstimulation syndrome.
  
  
  METHODS
  ES-IVM.
  
  
  METHODS
  Oocyte yield, maturation, fertilization, embryo quality, implantation, clinical pregnancy, and live-birth rate were analyzed.
  
  
  RESULTS
  The average number of oocytes retrieved was 16.7 ± 5.9, with a 52.1% maturation rate and a 58% fertilization rate by intracytoplasmic sperm injection. The average number of embryos transferred was 2.85 ± 0.6. The implantation rate was 17.5%, the clinical pregnancy rate was 40%, and the live-birth rate was 40%.
  
  
  CONCLUSIONS
  The efficiency of ES-IVM appears to be similar to natural cycle and low-stimulation IVM protocols with respect to laboratory and clinical outcomes, while eliminating the need for FSH stimulation and cycle monitoring.
authors.affiliation: Division of Reproductive Endocrinology and Infertility, Women and Infants Hospital of Rhode Island, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.
authors.forename: Wendy S
authors.initials: WS
authors.lastname: Vitek
authors.forename: Jeannine
authors.initials: J
authors.lastname: Witmyer
authors.forename: Sandra A
authors.initials: SA
authors.lastname: Carson
authors.forename: Jared C
authors.initials: JC
authors.lastname: Robins
mesh_terms: D000328:Adult; D046149:Embryo Culture Techniques; D010064:Embryo Implantation; D004958:Estradiol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005298:Fertility / Q000187:drug effects*; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D006801:Humans; D059471:In Vitro Oocyte Maturation Techniques / Q000379:methods*; D007247:Infertility, Female / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D050498:Live Birth; D054315:Oocyte Retrieval; D009865:Oocytes / Q000187:drug effects*; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000503:physiopathology; D011247:Pregnancy; D018873:Pregnancy Rate; D020554:Sperm Injections, Intracytoplasmic; D016896:Treatment Outcome
chemical_list: D005300:Fertility Agents, Female; D004958:Estradiol